OpenQ, a provider of solutions to enable life sciences and health companies to overcome compliance and exposure risks, introduced OpenQ SafeGuard™, a social enterprise compliance suite for managing social compliance risk. This patent-pending technology allows companies with social compliance risk to consolidate internal and external feeds and shared files from social media and other collaboration tools to deliver accurate and complete archiving, proactive analysis, real-time review auditing and remediation.
SafeGuard™ collects activity feeds, posts and documents from social platforms, and other enterprise interactions, to proactively identify and classify business and compliance risk. An intuitive interface enables the efficient management of compliance cases with classification of risk level according to industry driven and company-defined priorities.
“Social platforms are revolutionizing business by improving a company’s ability to collaborate internally and with customers, reduce costs and improve a product’s competitive advantage,” said Jim Zuffoletti, President, OpenQ. “However, many companies are fearful of leaking trade secrets, incurring liabilities, or committing compliance violations and have been slow to go ‘Social’. With SafeGuard companies that are concerned with regulatory compliance, privacy, internal communication firewalls and brand consistency can embrace Social business and be confident that they are getting proactive, real-time risk analysis, classification and archiving.”
Added Otavio Freire, Chief Technology Officer, OpenQ. “SafeGuard enables faster enterprise adoption of social collaboration and allows companies to benefit from the value created by new, social technologies for today and tomorrow. SafeGuard can work as a stand-alone system or be integrated into current social media search and archiving tools. Most importantly, SafeGuard allows you to create social policies for specific channels and enforce the policies guaranteeing that they stand-up to internal audit processes.”
The product was discussed during a complimentary webinar "Leveraging Social Media Communities for Compliant Collaboration with Specialty Key Opinion Leaders" with Pharmaceutical Executive magazine, yesterday and can be viewed on-demand for free at www.pharmexec.com/socialmedia.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
2 Commerce Drive
Cranbury, NJ 08512